Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$27.51 - $27.51 $651,987 - $651,987
23,700 Added 43.65%
78,000 $2.15 Million
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $2.26 Million - $2.85 Million
-90,100 Reduced 62.4%
54,300 $1.43 Million
Q1 2024

May 14, 2024

BUY
$30.27 - $43.79 $4.37 Million - $6.32 Million
144,400 New
144,400 $4.67 Million
Q4 2021

Feb 11, 2022

SELL
$7.33 - $9.32 $219,900 - $279,600
-30,000 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$9.4 - $16.85 $376,000 - $674,000
-40,000 Reduced 57.14%
30,000 $317,000
Q1 2021

May 14, 2021

BUY
$13.08 - $49.6 $915,600 - $3.47 Million
70,000 New
70,000 $1.12 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.